In its November 2023 Proposed Rule and in its recently issued Final Rule that was published in the Federal Register on April 23, 2024, the Centers for Medicare & Medicaid Services (CMS).
different model, which will allow rapid, often near automatic sign off for medicines and technologies already approved by trusted regulators in other parts of the world such as the united states, europe and japan. at the same time, they will set up a swift new approval process for the most cutting edge medicines and devices, to ensure the uk becomes a global centre for their development, and with an extra £10 million of funding over the next two years they will put in place the quickest, simplest regulatory approval in the world for companies seeking rapid market access. we are proud of the life science sector, which received more inward investment than any in europe last year. today s change will make the uk and even more exciting place to invest, using our brexit freedoms and speeding up access for nhs patients to the very newest drugs. today, with our talented science,